Türk Klinik ve Laboratuvar Dergisi Cilt 2 : Sayı 4

Abstract

Keywords

• -

References

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357:266-81.
2. Atli T, Gullu S, Uysal AR, Erdogan G. The prevalence of Vitamin D deficiency and effects of ultraviolet light on Vitamin D levels in elderly Turkish population. Arch Gerontol Geriatr. 2005; 40:53-60.
3. Pehlivan I, Hatun S, Aydoğan M, Babaoğlu K, Gökalp AS. Maternal vitamin D deficiency and vitamin D supplementation in healthy infants. Turk J Pediatr. 2003; 45:315-20.
4. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Mi- callef IN et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol. 2010; 28:4191-8.
5. Mathiasen IS, Lademann U, Jäättelä M. Apoptosis induced by vita- min D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 1999; 59:4848-56.
6. Naveilhan, P., Berger, F., Haddad, K., Barbot, N., Benabid, A.-L., Brachet, P., and Wion, D. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors. J. Neurosci. Res. 1994; 37: 2178–86.
7. Vieth, R. The mechanism of vitamin D toxicity. Bone Miner. 1990; : 267–72.
8. Crew KD, Shane E, Cremers S et al: High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009; :2151-6.

9. Chen P, Hu P, Xie D, et al: Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 2010; 121:469
10. Gorham ED, Garland CF, Garland FC et al: Vitamin D and preven- tion of colorectal cancer. J Steroid Biochem Mol Biol 2005; 97:179-94.
11. Yin L, Grandi N, Raum E et al: Meta-analysis: Longitudinal studi- es of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30:113-25.
12. Ng AC, Kumar SK, Rajkumar SV et al: Impact of vitamin D defi- ciency on the clinical presentationand prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 2009; 84:397-400.
13. Schwartz GG. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol. 2009; 19:96-102.
14. Fiscella K, Winters P, Tancredi D, Hendren S, Franks P. Racial dis- parity in death from colorectal cancer: Does vitamin D deficiency cont- ribute? Cancer. 2011; 117:1061-9.
15. Hanchette CL, Schwartz GG. Geographic patterns of prostate can- cer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer. 1992; 70:2861–69.
16. Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, Helzlsouer KJ, McCullough ML, Setiawan VW et al. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:36-46.
17. Gallicchio L, Moore LE, Stevens VL, Ahn J, Albanes D, Hartmul- ler V et al. Circulating 25-hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:47-57.
18. Zheng W, Danforth KN, Tworoger SS, Goodman MT, Arslan AA, Patel AV et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:70-80.
19. Purdue MP, Freedman DM, Gapstur SM, Helzlsouer KJ, Laden F, Lim U et al. Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:58-69.
20. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI. Se- rum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res. 2010; 70:8587-97.
21. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ et al. Circulating 25-hydroxyvitamin D and risk of panc- reatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:81-93.
22. Abnet CC, Chen Y, Chow WH, Gao YT, Helzlsouer KJ, Le Marc- hand L et al. Circulating 25-hydroxyvitamin D and risk of esophage- al and gastric cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:94-106.
23. Harriss DJ, Atkinson G, George K, Cable NT, Reilly T, Haboubi N et al. Lifestyle factors and colorectal cancer risk (1): systematic revi- ew and meta-analysis of associations with body mass index. Colorectal Dis. 2009; 11:547-63.
24. Lagunova Z, Porojnicu AC, Grant WB, Bruland Ø, Moan JE. Obe- sity and increased risk of cancer: does decrease of serum 25-hydroxyvi- tamin D level with increasing body mass index explain some of the as- sociation? Mol Nutr Food Res. 2010; 54:1127-33.
25. Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, et al. a,25d Dihydroxyvitamin D3 and 1 a-hydroxyvitamin D3 prolong sur- vival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci U S A. 1983; 80:201–4.
26. Tobler A, Koeffler HP. Differentiation of human acute myelogenc- res leukemia cells: Therapeutic possibilities. Acta Haematol. 1987; 78 (Suppl 1): 127–35.
27. Osborn JL, Schwartz GG, Smith DC, Bahnson RR, Day R, Trump DL. Phase II trial of oral 1,25-Dihydroxyvitamin D (Calcitriol) in hor- mone refractory prostate cancer. Urologic Oncol. 1995; 1:195–8.
28. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, et al. Do- ubleblinded randomized study of high-dose calcitriol plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT in- vestigators. J Clin Oncol. 2007; 25:669–74.
29. Zheng Y, Zhou H, Ooi LL, Snir AD, Dunstan CR, Seibel MJ. Vi- tamin D deficiency promotes prostate cancer growth in bone. Prostate. ; 71:1012-21.
30. Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, Seibel MJ, Dunstan CR. Vitamin D deficiency promotes human breast can- cer growth in a murine model of bone metastasis.Cancer Res. 2010; :1835-44.
31. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC. Immunocytochemical detection of 1,25-dihydroxy- vitamin D receptors in normal human tissues. J Clin Endocrinol Metab ; 67:607–13. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ et al. A phase II study of the vitamin D analogue Seocalcitol in pa- tients with inoperable hepatocellular carcinoma. Br J Cancer. 2003; :252-7.
32. Miyaguchi S, Watanabe T. The role of Vitamin D3 receptor mRNA in the proliferation of hepatocellular carcinoma. Hepatogastroentero- logy 2000; 47:468–72.
33. Wu FS, Zheng SS, Wu LJ, Teng LS, Ma ZM, Zhao WH, Wu W. Cal- citriol inhibits the growth of MHCC97 heptocellular cell lines by down- modulating c-met and ERK expressions. Liver Int. 2007; 27:700-7.
34. Pourgholami MH, Morris DL. 1,25-Dihydroxyvitamin D3 in lipio- dol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies.J Steroid Biochem Mol Biol. 2004; 89-90:513-8.
35. Jacobs ET, Thomson CA, Flatt SW, Al-Delaimy WK, Hibler EA, Jo- nes LA et al. Vitamin D and breast cancer recurrence in the Women’s Healthy Eating and Living (WHEL) Study.Am J Clin Nutr. 2011; :108-17.
36. Lee MS, Huang YC, Wahlqvist ML, Wu TY, Chou YC, Wu MH et al. Vitamin d decreases risk of breast cancer in premenopausal women of normal weight in subtropical taiwan. J Epidemiol. 2011; 21:87-94.
37. Kawase T, Matsuo K, Suzuki T, Hirose K, Hosono S, Watanabe M et al. Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Can- cer Sci. 2010; 101:1234-40.
38. Vashi PG, Trukova K, Lammersfeld CA, Braun DP, Gupta D. Im- pact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutr J. 2010; 9:60.
39. Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR, et al. Vitamin D, calcium supplementation, and colorectal adeno- mas: results of a randomized trial. J Natl Cancer Inst 2003; 95:1765–71.
40. Ahearn TU, McCullough ML, Flanders WD, Long Q, Sidelnikov E, Fedirko V et al. A randomized clinical trial of the effects of supplemen- tal calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients. Cancer Res. 2011; 71:413-23.
41. McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flan- ders WD, Koenig K et al. Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:21-35.
42. Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009; 30:1170-80.
43. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009; 29:3511-36.
44. Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E et al. Vitamin D receptor gene polymorphisms and hepatocellular carci- noma in alcoholic cirrhosis. World J Gastroenterol. 2010; 16:3016-24.
45. Sorumlu Yazar: Dr. Akif ALTINBAŞ Emrah Mah Göksel Sok. No:27/8 İncirli, Ankara Tel: [phone]
46. E-mail: [e-mail] Grossman RI, Yousem DM. Nöroradyoloji Bilinmesi Gerekenler. 2. baskıdan çeviri. İzmir, İzmir Güven Kitabevi. 2009. p.406-407.
47. Michel SJ, Given CA 2nd, Robertson WC Jr. Imaging of the brain, in- cluding diffusion-weighted imaging in methylmalonic acidemia. Pedi- atr Radiol 2004;34:580–582.
48. Brismar J, Ozand PT. CT and MR of the brain in disorders of the pro- pionate and methylmalonate metabolism. AJNR 1994;15:1459–1473.
49. Yesildag A, Ayata A, Baykal B, Koroglu M, Yildiz H, Oral B, Oktem F, Oyar O.Magnetic resonance imaging and diffusion-weighted ima- ging in methylmalonic acidemia. Acta Radiol 2005;46:101-3.
50. Bindu PS, Kovoor JM, Christopher R. Teaching NeuroImages: MRI in methylmalonic acidemia. Neurology. 2010;74:e14.
51. Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. Can- cer 1995; 76; 2312–2318.
52. Fukuda A, Hirohata T, Noguchi S, Ikeda M, Matsuo K, Yoshida A. Risks for malignancies in patients with chronic thyroiditis: a long term follow-up study. Jpn. J. Cancer Res. 1987; 78; 1329–1334.
53. Li Volsi VA. Papillary neoplasms of the thyroid. Pathologic and prognostic features. Am. J. Clin. Pathol. 1992; 97; 426–443.
54. Tularemi. Hastalığının Kontrolü İçin Saha Rehberi. T.C. Sağlık Bakanlığı, Temel Sağlık Hizmetleri Genel Müdürlüğü, Zoonotik Hastalıklar Daire Başkanlığı, Ankara, 2011.
55. Bostancı S. Tulareminin kontrolü için Sağlık Bakanlığı’nca yapılan çalışmalar. III. Türkiye Zoonotok Hastalıklar Sempozyumu, 1-2 Kasım ,Ankara, Sempozyum Kitabı,s.19-22. Karadenizli A. Tularemi: Etken ve epidemiyoloji. III. Türkiye Zoo- notok Hastalıklar Sempozyumu, 1-2 Kasım 2010,Ankara, Sempozyum Kitabı,s.8-12.
56. Tekin M,Çam OH, Acar G, kaytancı E, Hanege FM. Göztepe Tıp Dergisi 26(1):46-50, 2011
57. Bıçakçı Z. Lenfadenopati Ayırıcı Tanısında Az Bilinen Bir Zoonoz: Orofarengeal Tularemi. 35. Ulusal Hematoloji Kongresi, 7-10 Ekim ; Antalya, Kongre Kitabı, s: 119-124. Eyibilen A, Ekinci A, Aladağ i. Servikal lenfadenit nedeni olarak tu- laremi. Dicle Tıp Dergisi,38(1) :76-78. Ulu Kılıç A, Kılıç S, Sencan I, Ciçek Şentürk G, Gürbüz Y, Tütüncü EE. A water-borne tularemia outbreak caused by Francisella tularensis subspecies holarctica in Central Anatolia region. Mikrobiyol Bul. 2011; (2):234-47.
58. Sencan I, Sahin I, Kaya D, Oksuz S, Ozdemir D, Karabay O. An out- break of oropharyngeal tularemia with cervical adenopathy predomi- nantly in the left side. Yonsei Med J. 2009; 50 (1):50-4.
59. Ozdemir D, Sencan I, Annakkaya AN, Karadenizli A, Guclu E, Sert E,et al. , Comparison of the 2000 and 2005 outbreaks of tularemia in the Duzce region of Turkey. Jpn J Infect Dis. 2007; 60(1):51-2.
60. Leblebicioglu H, Esen S, Turan D, Tanyeri Y, Karadenizli A, Ziyagil F, Goral G. Outbreak of tularemia: case-control study and environmen- tal investigation in Turkey. Int J Infect Dis 2008; 12:265-269.
61. Acicbe Ö,Aydın H, Doğancı L. Havza/ samsun bölgesi’nde tulare- mi endemisi: izlenen olgularının retrospektif yorumu. İnfeksiyon Der- gisi (Turkish Journal of Infection) 2007; 21 (2): 55-58.
62. Karadenizli A, Gurcan S, Kolayli F, Vahaboglu H. Outbreak of tu- laraemia in Golcuk, Turkey in 2005: Report of 5 cases and an overview of the literature from Turkey. Scand J Infect Dis 2005;37(10):712-6.
63. Gürcan Ş. Eskiocak M, Varol G, tularemi re-emerging in European part of Turkey after 60 years. Jpn J Infect Dis 2006; 59: 391-393.
64. Helvacı S, Gedikoglu S, Akalın H, Oral HB. Tularemia in Bursa, Turkey: 205 cases in ten years. Eur J Epidemiol 2000; 16: 271-276.
65. Willke A, Finke EJ, Grunow R, Sayan M, Erdogan S, Gedikoglu S.Evaluation of clinical, laboratory, and therapeutic features of 145 tu- laremia cases: the role of quinolones in oropharyngeal tularemia. AP- MIS 2008; 116(1): 66-73.
66. Engin A, Altuntaş E, Cankorkmaz L, Kaya A, Elaldı N, Şimşek H. Sivas ilinde saptanan ilk tularemi salgını: 29 olgunun değerlendirilmesi. Klimik Dergisi 2011; 24(1): 17-23.
67. Olgu sunumlarının giriş ve tartışma kısımları kısa-öz olmalı, kaynak sayısı 15 den az olmalıdır. Kısa raporlara özet yazılmamalı, en fazla 5 adet anahtar kelime, 10 kaynak, 1500 kelime, 2 tablo ve/veya şekil olma- lı ve yazının hemen sonunda sırasıyla yazar isimleri, ünvanları ve yazışma adresleri bulunmalıdır.
68. Editöre mektup, dergide daha önce yayımlanmış yazılara bilimsel eleştiri yapmak, katkı sağlamak ya da orjinal bir ça- lışma olarak sunulmamış veya sunulamayacak bilgilerin paylaşılması amacıyla hazırlanmış en fazla 1000 kelimeden olu- şan, kısa-öz ve 6 dan az sayıda kaynağı olmalı özet içermemelidir.